Mostrar el registro sencillo del ítem

Survival benefit of mantle cell lymphoma patients enrolled in clinical trials : a joint study from the LYSA group and French cancer registries

dc.rights.licenseopenen_US
dc.contributor.authorAUGUSTIN, A.
dc.contributor.authorLE GOUILL, S.
dc.contributor.authorGRESSIN, R.
dc.contributor.authorBERTAUT, A.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMONNEREAU, Alain
dc.contributor.authorWORONOFF, A. S.
dc.contributor.authorTRETARRE, B.
dc.contributor.authorDELAFOSSE, P.
dc.contributor.authorTROUSSARD, X.
dc.contributor.authorMOREAU, A.
dc.contributor.authorHERMINE, O.
dc.contributor.authorMAYNADIE, M.
dc.date.accessioned2020-10-19T07:15:08Z
dc.date.available2020-10-19T07:15:08Z
dc.date.issued2018-04
dc.identifier.issn0171-5216en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/11388
dc.description.abstractEnPURPOSE: Mantle cell lymphoma (MCL) is a rare non-Hodgkin's lymphoma entity with a poor prognosis. Therapeutic advances have improved the survival of patients enrolled in clinical trials; however, their impact on patients outside clinical trials remains unclear. In this work, we compared patient outcome inside and outside clinical trials. METHODS: We identified MCL patients recorded in six French population-based registries between 2008 and 2012 to perform a comparison with patients enrolled in two prospective multicenter MCL clinical trials conducted by the LYSA group during the same period. Variables associated with inclusion in a clinical trial were identified using a logistic regression. Pohar-Perme estimator and Nelson et al. flexible parametric model was used to estimate net survival probabilities and prognosis factors on excess mortality. RESULTS: A total of 312 registry patients were compared to the 372 patients enrolled in LYSA clinical trials. Patients included in clinical trials were younger (median age 60 vs 74, p < 0.001). Age and Ann Arbor stage IV were independently associated with enrollment [OR = 0.09 (0.06-0.12) and OR = 1.61 (1.11-2.34), respectively]. The 4 year net survival was better in clinical trials [79.9% (75.9-84.7) vs 60.3% (53.6-67.0)]. This result was confirmed in multivariate analysis in patients older than 65 years with a lower excess mortality rate [0.33 (0.17-0.66)]. CONCLUSIONS: MCL included in trials are highly selected patients who are not representative of MCL patients who are encountered in everyday practice. With widened inclusion criteria, clinical trial patients could be more representative of the general population.
dc.language.isoENen_US
dc.subject.enEPICENE
dc.title.enSurvival benefit of mantle cell lymphoma patients enrolled in clinical trials : a joint study from the LYSA group and French cancer registries
dc.title.alternativeJ Cancer Res Clin Oncolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1007/s00432-017-2529-9en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed29022078en_US
bordeaux.journalJournal of cancer research and clinical oncologyen_US
bordeaux.page629-635en_US
bordeaux.volume4en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamEPICENE_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&amp;rft.date=2018-04&amp;rft.volume=4&amp;rft.spage=629-635&amp;rft.epage=629-635&amp;rft.eissn=0171-5216&amp;rft.issn=0171-5216&amp;rft.au=AUGUSTIN,%20A.&amp;LE%20GOUILL,%20S.&amp;GRESSIN,%20R.&amp;BERTAUT,%20A.&amp;MONNEREAU,%20Alain&amp;rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem